Related references
Note: Only part of the references are listed.Genotyping and Genomic Profiling of Non-Small-Cell Lung Cancer: Implications for Current and Future Therapies
Tianhong Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Cancer treatment and survivorship statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
EGFR Molecular Profiling in Advanced NSCLC A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy
Michele Milella et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Activation of Mammalian Target of Rapamycin Pathway Confers Adverse Outcome in Nonsmall Cell Lung Carcinoma
Dan Liu et al.
CANCER (2011)
Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non-Small Cell Lung Cancer
Akihiko Yoshizawa et al.
CLINICAL CANCER RESEARCH (2010)
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Increased activated Akt expression in renal cell carcinomas and prognosis
Martina Hager et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2009)
The PI3-K/AKT-Pathway and Radiation Resistance Mechanisms in Non-small Cell Lung Cancer
Olga C. J. Schuurbiers et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Molecular predictive and prognostic markers in non-small-cell lung cancer
Linda E. Coate et al.
LANCET ONCOLOGY (2009)
Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer
Shinobu Hosokawa et al.
LUNG CANCER (2009)
Akt as a therapeutic target in cancer
Linda S. Steelman et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2008)
Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer An Analysis of Patients from German Centers in the TRUST Study
Claus-Peter Schneider et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Increased staining for phosphorylated AKT and nuclear factor-κB p65 and their relationship with prognosis in epithelial ovarian cancer
Rui-Xia Guo et al.
PATHOLOGY INTERNATIONAL (2008)
Prognostic value of integrin ß1-ILK-pAkt signaling pathway in non-small cell lung cancer
Mayumi Okamura et al.
HUMAN PATHOLOGY (2007)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
Correlation between EGFR gene mutation pattern and Akt phosphorylation in pulmonary adenocarcinomas
Satoshi Ikeda et al.
PATHOLOGY INTERNATIONAL (2007)
Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma
Junji Tsurutani et al.
LUNG CANCER (2007)
Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis
JM Tang et al.
LUNG CANCER (2006)
Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors
J Tsurutani et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Akt activation correlates with adverse outcome in tongue cancer
E Massarelli et al.
CANCER (2005)
Perturbations of the AKT signaling pathway in human cancer
DA Altomare et al.
ONCOGENE (2005)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
F Cappuzzo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Phospho-Akt expression is associated with a favorable outcome in non-small cell lung cancer
A Shah et al.
CLINICAL CANCER RESEARCH (2005)
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib
SW Han et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases
DL Dai et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa (R), ZD1839) in chemotherapy-resistant non-small cell lung cancer
SW Han et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
R Sordella et al.
SCIENCE (2004)
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer
F Cappuzzo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression
PP Massion et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Relation of epidermal growth factor receptor, phosphorylated-Akt, and hypoxia-inducible factor-1α in non-small cell lung cancers
Y Hirami et al.
CANCER LETTERS (2004)
Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage
O David et al.
CLINICAL CANCER RESEARCH (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells
KA West et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
PKB binding proteins: Getting in on the akt
DP Brazil et al.
CELL (2002)
The protein kinase B/Akt signalling pathway in human malignancy
KM Nicholson et al.
CELLULAR SIGNALLING (2002)
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
G Pérez-Tenorio et al.
BRITISH JOURNAL OF CANCER (2002)
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis
E Steels et al.
EUROPEAN RESPIRATORY JOURNAL (2001)
Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis
JAC Sterne et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2001)
Share Paper
